Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $9.33 Average Price Target from Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have been given a consensus recommendation of “Hold” by the five analysts that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $9.33.

Several equities research analysts have issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $8.00 target price on shares of Esperion Therapeutics in a research note on Wednesday, April 10th. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research note on Monday, March 25th. Finally, Bank of America cut Esperion Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 3rd.

Institutional Investors Weigh In On Esperion Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Spire Wealth Management grew its stake in shares of Esperion Therapeutics by 69.2% in the fourth quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 7,267 shares in the last quarter. Private Portfolio Partners LLC acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at $30,000. Herbst Group LLC acquired a new stake in shares of Esperion Therapeutics in the first quarter valued at $28,000. PSI Advisors LLC grew its stake in shares of Esperion Therapeutics by 161.5% in the fourth quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 10,500 shares in the last quarter. Finally, GSA Capital Partners LLP grew its stake in shares of Esperion Therapeutics by 1.0% in the fourth quarter. GSA Capital Partners LLP now owns 1,128,149 shares of the biopharmaceutical company’s stock valued at $3,373,000 after buying an additional 11,494 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Stock Performance

NASDAQ:ESPR opened at $2.13 on Friday. Esperion Therapeutics has a one year low of $0.70 and a one year high of $3.40. The stock has a market cap of $403.42 million, a PE ratio of -1.00 and a beta of 0.84. The stock has a 50 day moving average price of $2.43 and a 200 day moving average price of $1.98.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.03. The company had revenue of $32.25 million during the quarter, compared to analyst estimates of $26.84 million. During the same period in the prior year, the business posted ($0.76) EPS. As a group, analysts predict that Esperion Therapeutics will post -0.68 earnings per share for the current fiscal year.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.